DDIAS and lung carcinoma: DDIAS is involved in the resistance of lung cancer to DNA-damaging agents, such as cisplatin and camptothecin, as well as in the resistance of lung cancer and hepatocellular carcinoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)3,4,6,7.